Brokers Offer Predictions for MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Equities research analysts at Diamond Equity issued their Q1 2025 earnings per share estimates for shares of MAIA Biotechnology in a report issued on Thursday, November 14th. Diamond Equity analyst H. Diamond expects that the company will earn ($0.25) per share for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.25) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.35) EPS.

MAIA Biotechnology Price Performance

MAIA Biotechnology stock opened at $2.35 on Monday. MAIA Biotechnology has a one year low of $0.82 and a one year high of $5.99. The firm has a market capitalization of $59.53 million, a PE ratio of -1.70 and a beta of 0.32.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.21.

Insider Transactions at MAIA Biotechnology

In other MAIA Biotechnology news, Director Cristian Luput bought 22,133 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were acquired at an average cost of $2.51 per share, for a total transaction of $55,553.83. Following the purchase, the director now directly owns 389,483 shares of the company’s stock, valued at $977,602.33. The trade was a 6.03 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 36.98% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in MAIA Biotechnology during the third quarter valued at about $31,000. Mather Group LLC. increased its position in shares of MAIA Biotechnology by 50,150.0% during the 2nd quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock valued at $41,000 after purchasing an additional 12,036 shares during the last quarter. Ground Swell Capital LLC purchased a new position in shares of MAIA Biotechnology during the 2nd quarter valued at about $56,000. Virtu Financial LLC bought a new stake in MAIA Biotechnology in the 1st quarter worth approximately $71,000. Finally, Geode Capital Management LLC boosted its stake in MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after buying an additional 35,821 shares in the last quarter. 5.65% of the stock is currently owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.